Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the efficacy of Udenafil (Zydena®, Dong-A Pharmaceutical co., Ltd, Seoul, Korea) in treatment of erectile dysfunction after radical resection for sigmoid colon and rectal cancer. In this study, the efficacy of Udenafil will be evaluated in treatment for patient with chronic erectile dysfunction, which developed after radical resection for sigmoid and rectal cancer and continues 12 months after the surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Udenafil

Criteria

Inclusion Criteria:

• • Male patients between 19-70 years old in good general health

• Patient willing to treat postoperative erectile dysfunction and participate in the study

• Patient who understands and accepts to sign the informed consent form

• Patient who received radical resection for sigmoid colon and rectal cancer. :

erectile dysfunction was developed following operation, not preoperatively

• Scores of IIEF-5 measured at 12 months after surgery is 16 or less

Exclusion Criteria:

• • Documented problem of preoperative erectile dysfunction

• Past history of myocardial infarction, cerebrovascular disease

• Under administration of nitrate

• Liver dysfunction (SGOT or SGPT 100 IU/L or more)

• Kidney dysfunction (serum Creatinine 3mg/dl or more)